Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology | Hematology
Clinical Trials: Chronic Lymphocytic Leukemia
A listing of clinical trials currently looking for volunteers to enroll in Chronic Lymphocytic Leukemia studies. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham : University of Alabama at Birmingham
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Huntsville : Clearview Cancer Institute
A Extension Study of GS-1101 for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116
Huntsville : Clearview Cancer Institute
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Huntsville : Clearview Cancer Institute
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Huntsville : Clearview Cancer Institute
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
View More »
Huntsville : Clearview Cancer Institute
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Huntsville : Clearview Cancer Institute
Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Huntsville : TG Therapeutics Investigational Trial Site
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
Muscle Shoals : Northwest Alabama Cancer Center, PC
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Arizona
Scottsdale : Mayo Clinic Arizona - Cancer Clinical Research Unit
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Tucson : Arizona Oncology Associates
A Extension Study of GS-1101 for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116
Tucson : Arizona Oncology Associates
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Tucson : University of Arizona (SPORE)
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
California
Duarte : City of Hope
Acquisition of Peripheral Blood and/or Bone Marrow Aspirate from Patients with Chronic Lymphocytic Leukemia for Method Development of
Aptamers Based Delivery Method of RNAi
Duarte : City of Hope
An Open Label, Multicenter, Phase 1b Trial of GA101 (RO5072759) in Combination with Chemotherapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia
La Jolla : Moores UCSD Cancer Center
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
Santa Maria : Central Coast Medical Oncology Corp.
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
Stanford : Stanford University School of Medicine
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
Sunnyvale : Pharmacyclics
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
View More »
Burbank : East Valley Hematology and Oncology Medical Group
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Concord : Bay Area Cancer Research Group
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Fountain Valley : Lalita Pandit, MD, Inc.
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Fountain Valley : Pacific Coast Hematology/Oncology Medical Group, Inc.
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Fountain Valley : Robert A. Moss, M.D. FACP, Inc.
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
La Jolla : University of California, San Diego - Moores Cancer Center
A Extension Study of GS-1101 for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116
La Jolla : Site Reference ID/Investigator# 48325
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
La Jolla : Site Reference ID/Investigator# 70398
A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed or Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
La Jolla : University of California, San Diego/Moores Cancer Center
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
La Jolla : University of California, San Diego- Moores Cancer Center
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
La Jolla : Scripps Cancer Center
A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia
La Jolla : Moores UCSD Cancer Center
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
La Jolla : Moores Ucsd Cancer Center
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
La Jolla : University of California, San Diego
Multi-center Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
La Jolla : University of California San Diego
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
La Jolla : Moores UCSD Cancer Center
Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia
La Jolla : UCSD Medical Center
Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL)
Los Angeles : UCLA
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Los Angeles : Metropolitan Hematology Oncology Medical Group
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Los Angeles : Ucla-Division Of Hematology/Oncology
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
Los Angeles : UCLA
Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Mission Hills : Providence Holy Cross Medical Center
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Oceanside : North County Oncology
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Oxnard : Ventura County Hematology Oncology Specialists
A Extension Study of GS-1101 for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116
Oxnard : Ventura County Hematology Oncology Specialists
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Oxnard : PMK Medical Group Inc., DBA Ventura County Hematology Oncology Specialists
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Oxnard : Ventura County Hematology Oncology Specialists
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Palo Alto : Stanford Cancer Center
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Palo Alto : Stanford Cancer Center
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Palo Alto : Stanford Cancer Center
Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Rancho Mirage : Cancer and Blood Institute Medical Group
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
San Diego : Moores UCSD Cancer Center
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Santa Monica : UCLA Medical Center
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Santa Monica : UCLA
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Stanford : Stanford Cancer Center
A Extension Study of GS-1101 for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116
Stanford : Stanford Cancer Center
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Stanford : Stanford Cancer Center - Stanford University
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Stockton : St. Teresa Comprehensive Cancer Center
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Vista : Medical Group of North County
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Colorado
Aurora : Investigational Site Number 840004
Study Combining SAR245409 With Bendamustine and/or Rituximab in Subjects With Indolent Lymphoma, Mantle Cell Lymphoma & Chronic Lymphocytic Leukemia
Colorado Springs : The Oncology Clinic, PC
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Denver : Rocky Mountain Blood and Marrow Transplant Program
A Extension Study of GS-1101 for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116
Denver : Rocky Mountain Cancer Center
A Extension Study of GS-1101 for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116
Denver : Rocky Mountain Cancer Center
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
View More »
Denver : Rocky Mountain Blood and Marrow Transplant Program
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Denver : Rocky Mountain Cancer Center
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Denver : Rocky Mountain Cancer Centers - Denver
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Denver : Mile High Oncology
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Connecticut
Norwalk : Whittingham Cancer Center at Norwalk Hospital
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
View More »
New Haven : Yale Cancer Center
Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia
District of Columbia
Washington : Georgetown University Medical Center Lombardi Cancer Center
A Extension Study of GS-1101 for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116
Washington : Georgetown University Medical Center Lombardi Cancer Center
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Washington : Georgetown University
Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Washington : Georgetown University Hospital/Lombardi Cancer Center
Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)
Florida
Atlantis : Medical Specialists of the Palm Beaches
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Boynton Beach : Collaborative Research Group
A Extension Study of GS-1101 for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116
Boynton Beach : Collaborative Research Group LLC
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Boynton Beach : Thomas Niederman, MD
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Boynton Beach : University Cancer Institute
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
View More »
Boynton Beach : Palm Beach Institute of Hematology and Oncology
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Fort Myers : Florida Cancer Specialists
A Extension Study of GS-1101 for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116
Fort Myers : Florida Cancer Specialists
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Gainsville : University of Florida
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Gainsville : University of Florida
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Jacksonville : Integrated Community Oncology Network
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Jacksonville : Mayo Clinic
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Kissimmee : Osceola Cancer Center
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
New Port Richey : Pasco Hernando Oncology Associates (Kumar)
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
New Port Richey : Pasco Hernando Oncology Associates, PA
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
New Port Richey : Pasco Pinellas Cancer Center
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Ocala : Ocala Oncology Center
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
St. Petersburg : Florida Cancer Specialists
A Extension Study of GS-1101 for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116
St. Petersburg : Florida Cancer Specialists
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Tampa : H. Lee Moffitt Cancer Center and Research Institute
Ofatumumab/Methylprednisolone Followed by Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Tampa : H. Lee Moffitt Cancer Center and Research Institute
Phase II Ofatumumab/Methylprednisolone Followed by Ofatumumab/Lenalidomide for Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Georgia
Albany : Phoebe Putney Memorial Hospital
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Atlanta : Georgia Cancer Specialists
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Atlanta : Peachtree Hematology-Oncology Consultants
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Augusta : Augusta Oncology Associates, PC
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Augusta : For additional information regarding sites for this trial call (919) 465-4648
Phase 1b Safety and Efficacy Study of TRU-016 and Rituximab in Previously Untreated Chronic Lymphocytic Leukemia
View More »
Augusta : Investigational Site Number 840006
Study Combining SAR245409 With Bendamustine and/or Rituximab in Subjects With Indolent Lymphoma, Mantle Cell Lymphoma & Chronic Lymphocytic Leukemia
Dublin : US Oncology - Dublin Hematology & Oncology
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Griffin : Spalding Oncology Services
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Marietta :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Hawaii
Honolulu : Straub Clinic and Hospital
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Idaho
Boise : St Luke's Mountain States Tumor Institute
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Illinois
Arlington Heights : US Oncology - Cancer Care & Hematology Specialists of Chicagoland - Arlington
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Chicago : Site Reference ID/Investigator# 71593
A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed or Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Chicago : Northwestern University
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Chicago : Rush University Medical Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Chicago : John H. Stroger, Jr., Hospital of Cook County
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
View More »
Chicago : Northwestern University
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Gurnee : Oncology Hematology Assoc. of Northern Illinois
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Harvey : Ingalls Cancer Research Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Lombard : Elmhurst Memorial Hospital
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Niles : Oncology Specialists, S.C.
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Niles : US Oncology - Cancer Care & Hematology Specialists of Chicagoland - Niles
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Peoria : Illinois Cancer Care
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Skokie : Orchard Research
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Urbana : Carle Cancer Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Winfield : US Oncology - Cancer Care & Hematology Specialists of Chicagoland - Winfield
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Indiana
Beech Grove : St. Francis Cancer Research
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Goshen :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Goshen : Center for Cancer Care @ Goshen Health Systems
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Indianapolis :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Indianapolis : Indiana University Simon Cancer Center IU Simon Cancer Center Clinical Research Office, RT 380
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
View More »
Indianapolis : Indiana University Cancer Center Clinical Research Office
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Indianapolis : Indiana Oncology Hematology Consultants
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Indianapolis : Indiana University Simon Cancer Center
Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies
Lafayette : Arnett Cancer Care
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Lafayette : Horizon Oncology Center
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Mishawaka : Cancer Care Partners, LLC
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
New Albany : Cancer Care Center, Inc.
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
New Albany : Cancer Care Center
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Iowa
Ames : McFarland Clinic
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Bettendorf : Hematology Oncology Associates of the Quad Cities
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Cedar Rapids : Iowa Blood and Cancer Care of PCI
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Waterloo : Covenant Clinic
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Kansas
Wichita : Cancer Center of Kansas, PA
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Kentucky
Hazard : Kentucky Cancer Clinic
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Louisville :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Paducah :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Louisiana
Baton Rouge : Mary Bird Perkins Cancer Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Marrero :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Maryland
Baltimore :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Baltimore : Chesapeake Oncology Hematology Associates
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Baltimore : Auerbach Hematology Oncology Associates, Inc.
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Baltimore : Greater Baltimore Medical Center
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Baltimore : B. Douglas Smith, M.D.
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
View More »
Bethesda : Center for Cancer & Blood Disorders, PC
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Bethesda : Center for Cancer and Blood Disorders
Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Cumberland : Western Maryland Health System, Inc.
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Westminster : Alliance Hematology Oncology, PA
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Massachusetts
Boston : Dana-Farber Cancer Institute
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
View More »
Boston : Site Reference ID/Investigator# 48324
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
Boston : Dana-Farber Cancer Institute
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Boston : Dana-Farber Cancer Institute
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Boston : Beth Israel Deaconess Medical Center
Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Boston : Dana-Farber Cancer Institute
Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Boston : Massachusetts General Hospital
Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Boston : Dana Farber Cancer Institute
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Boston : Dana Farber Cancer Institute
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
Boston : Dana-Farber Cancer Institute
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
Boston : Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
Hyannis : Capecod Hospital / Davenport Mugar Cancer Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Worcester : Fallon Clinic
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Michigan
Flint : Michigan State University / McLaren Regional Medical Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Flint : Genesee Cancer & Blood Disease Treatment Center, PC
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Freesoil : West Michigan Regional Cancer & Blood Center
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Grand Rapids : Cancer and Hematology Centers of Western Michigan
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Grand Rapids : Spectrum Health Hospitals
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
View More »
Kalamazoo : West Michigan Cancer Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Minnesota
Rochester : Mayo Clinic
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
View More »
Duluth : Duluth Clinic Cancer Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Minneapolis : Minnesota Oncology Hematology, PA
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Minneapolis : Minnesota Oncology Hematology P.A.
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Minneapolis : Novartis Investigative Site
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
Rochester : Mayo Clinic
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
St. Louis Park : Park Nicollet Institute - Louisiana Ave.
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
St. Louis Park : Park Nicollet Institute Metro - MN CCOP
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Mississippi
Missouri
Branson : Branson Oncology Clinic
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Columbia : US Oncology - Missouri Cancer Associates
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Jefferson City : Capitol Comprehensive Cancer Care Clinic
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Springfield : St. John's Medical Research Institute
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
St. Joseph : St. Joseph Oncology, Inc.
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
View More »
St. Louis :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
St. Louis : Washington University School of Medicine
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
St. Louis : Hematology Oncology Consultants, Inc.
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
St. Louis : St. Louis Hematology Oncology Specialists, Inc.
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
St. Louis : Washington University School of Medicine
Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Montana
Missoula : Montana Cancer Institute Foundation
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Nebraska
Lincoln : Nebraska Hematology Oncology, PC
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Lincoln : Southeast Nebraska Hematology & Oncology Consultants, PC
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Omaha : University of Nebraska Medical Center
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Nevada
Carson City : Sierra Nevada Oncology Care
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Las Vegas : Southern Nevada Cancer Research Foundation
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Las Vegas : Nevada Cancer Center
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Reno : VA Sierra Nevada Healthcare System
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
New Jersey
Cherry Hill : The Center for Cancer and Hematologic Disease
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Cherry Hill : The Center for Cancer and Hematologic Disease
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Elizabeth : Ellioth Fishkin, MD
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Englewood : Drs. Forte, Schleider, Attas & Condemi, PA
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Hackensack : Hackensack University Medical Center
A Extension Study of GS-1101 for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116
View More »
Hackensack : Hackensack University Medical Center
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Hackensack : Hackensack University Medical Center
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Hackensack :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Hackensack : Research Site
AMG 319 Lymphoid Malignancy FIH
Morristown : Hematology Oncology Associates of Northern New Jersey
A Extension Study of GS-1101 for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116
Morristown : Hematology Oncology Associates of Northern New Jersey
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Morristown : Hematology Oncology Associates of Northern New Jersey
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Morristown : Charles Farber, MD
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Morristown : Hematology Oncology of Northern New Jersey
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
New Brunswick : Investigational Site Number 840001
Study Combining SAR245409 With Bendamustine and/or Rituximab in Subjects With Indolent Lymphoma, Mantle Cell Lymphoma & Chronic Lymphocytic Leukemia
Somerville : Steeplechase Cancer Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
New York
New Hyde Park : CLL Research and Treatment Program
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
New Hyde Park : Biomedical Research Alliance of New York
Adults with Chronic Lymphocytic Leukemia are asked to participate in a research study being conducted by North Shore-Long Island Jewish Health System.
New Hyde Park : Biomedical Research Alliance of New York
Non-Hodgkin’s Lymphoma or Chronic Lymphocytic Leukemia
New York : New York Presbyterian Hospital/Cornell Medical Center
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
Rochester : Univ. of Rochester Cancer Center
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
View More »
Albany : New York Oncology Hematology, P.C.
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Albany : Samuel S Stratton VAMC
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Bay Shore : Hematology Oncology Associates of Western Suffolk
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Bronx : Bronx River Medical Associates
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Bronx : Eastchester Center for Cancer Care
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Bronxville : Eduardo Saponara, MD
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Buffalo : Jonah Cancer Care Center & ECMC
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Dunkirk :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Johnson City : Broome Oncology
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Mount Kisco : Westchester Hematology Oncology Associates
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
New Hyde Park : Long Island Jewish Medical Center
A Extension Study of GS-1101 for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116
New Hyde Park : Site Reference ID/Investigator# 71813
A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed or Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
New Hyde Park : Long Island Jewish Medical Center
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
New Hyde Park : Long Island Jewish Medical Center
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
New Hyde Park : Long Island Jewish medical Center
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
New Hyde Park : Long Island Jewish Medical Center
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
New Hyde Park : Long Island Jewish Medical Center
Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
New York : Site Reference ID/Investigator# 56810
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
New York : Memorial Sloan Kettering Cancer Center
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
New York : Weill Cornell Medical College
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
New York : Weill Cornell Medical College
Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (THRiL) as Initial Treatment for Patients With CLL
New York : Memorial Sloan-Kettering Cancer Center
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
New York : Weill Medical College of Cornell
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
New York : Mount Sinai School of Medicine & Mount Sinai Graduate School of biological Sciences
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
New York : Memorial Sloan-Kettering Cancer Center
Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age
New York : Weill Cornell Medical College
Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies
New York : Weill Medical College of Cornell
Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Rochester : University of Rochester Medical Center
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Syracuse : SUNY Upstate Medical University - Adult Program
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
North Carolina
Cary : US Oncology - Cancer Centers of North Carolina - Cary
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Durham : Site Reference ID/Investigator# 71393
A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed or Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Durham : Research Site
AMG 319 Lymphoid Malignancy FIH
Raleigh : US Oncology - Cancer Centers of North Carolina - Macon
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Raleigh : US Oncology - Cancer Centers of North Carolina - Falls
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
North Dakota
Bismarck :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Bismarck : Legacy Pharma Research
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Bismarck : Mid Dakota Clinic/Odyssey Research
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Fargo : Roger Maris Cancer Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Ohio
Columbus : The Ohio State University
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
View More »
Akron : Summa Health System - Cancer Research Office
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Akron : Summa Health System Hospitals
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Canton : Gabrail Cancer Center Research
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Canton : Nashat Y. Gabrail, MD, Inc.
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Cleveland : University Hospitals Case Medical Center
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Cleveland : Cleveland Clinic
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Columbus : The Ohio State University Comprehensive Cancer Center
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Columbus : The Ohio State University Medical Center
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Columbus : Mid Ohio Oncology / Hematology, Inc.
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Columbus : For additional information regarding sites for this trial call (919) 465-4648
Phase 1b Safety and Efficacy Study of TRU-016 and Rituximab in Previously Untreated Chronic Lymphocytic Leukemia
Elyria : Hematology Oncology Center, Inc.
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Oregon
Eugene : Willamette Valley Cancer Center
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Eugene : Willamette Valley Cancer and Research / USOR
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Eugene : US Oncology - Willamette Valley Cancer Institute - Eugene
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Portland : Northwest Cancer Specialists, PC
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Portland : Oregon Health & Science University
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
View More »
Portland : US Oncology - Northwest Cancer Specialists, PC - Portland - Barnes
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Portland : US Oncology - Northwest Cancer Specialists, PC - Portland - Broadway
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Portland : US Oncology - Northwest Cancer Specialists, PC - Portland - Hoyt
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Springfield : Willamette Valley Cancer Center
A Extension Study of GS-1101 for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116
Springfield : Willamette Valley Cancer Center
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Springfield : Willamette Valley Cancer Institute and Research Center
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Springfield : US Oncology - Willamette Valley Cancer Institute - Springfield
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Springfield : US Oncology Research: Willamette Valley Cancer Institute and Research Center
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Springfield : Willamette Valley Cancer Institute and Research Center
Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Tualatin : Northwest Cancer Specialists, PC
A Extension Study of GS-1101 for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116
Tualatin : Northwest Cancer Specialists, PC
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Tualatin : Northwest Cancer Specialists, P.C.
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Tualatin : US Oncology - Northwest Cancer Specialists, PC - Tualatin
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Pennsylvania
Philadelphia : University of Pennsylvania, Abramson Cancer Center
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
View More »
Bethlehem : Oncology Hematology of Lehigh Valley
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Drexel Hill : Consultants in Medical Oncology and Hematology, PC
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Gettysburg : Gettysburg Cancer Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Harrisburg : Andrews and Patel Associates
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Kingston : US Oncology - Medical Oncology Associates (Nahar)
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Lancaster : Lancaster Cancer Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Norristown : Luitpold Pharmaceuticals, Inc.
Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza® in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia
Philadelphia : Thomas Jefferson University
Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma
Reading : Berks Hematology Oncology Associates
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Rhode Island
Cranston : Hematology & Oncology Associates of Rhode Island
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Cranston : Sambandam and Joseph Associates, Inc
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
South Carolina
Charleston : Charleston Hematology Oncology
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Charleston : Charleston Hematology Oncology Associates, PA
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Charleston : Charleston Hematology Oncology, PA
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Charleston : Investigational Site Number 840002
Study Combining SAR245409 With Bendamustine and/or Rituximab in Subjects With Indolent Lymphoma, Mantle Cell Lymphoma & Chronic Lymphocytic Leukemia
Charleston : Medical University of South Carolina
Trial of Intracycle Sequential Ofatumumab and Lenalidomide for the Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab
View More »
Columbia : South Carolina Oncololgy Associates, PA
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Columbia : South Carolina Oncology Associates
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Easley : US Oncology - Cancer Centers of the Carolinas - Easley
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Greenville : Cancer Centers of the Carolinas
A Extension Study of GS-1101 for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116
Greenville : Cancer Centers of the Carolinas
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Greenville : Saint Francis Hospital
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Greenville : US Oncology - Cancer Centers of the Carlinas - Eastside
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Greenville : US Oncology - Cancer Centers of the Carolinas - Butternut
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Greenville : US Oncology - Cancer Centers of the Carolinas - West Faris
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Greenville : Greenville Hospital System
Trial of Intracycle Sequential Ofatumumab and Lenalidomide for the Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab
Seneca : US Oncology - Cancer Centers of the Carolinas - Seneca
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Spartanburg : US Oncology - Cancer Centers of the Carolinas - Spartanburg
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
South Dakota
Sioux Falls : Sanford Clinic
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Tennessee
Nashville : Vanderbilt-lngram
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
View More »
Bartlett : US Oncology - University of Tennessee Cancer Institute - Bartlett
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Collierville : Family Cancer Center, PLLC
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Collierville : The Family Cancer Center
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Germantown : US Oncology - University of Tennessee Cancer Institute - Germantown
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Germantown : C. Michael Jones, MD, PC
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Memphis : US Oncology - University of Tennessee Cancer Institute - Memphis
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Nashville : Sarah Cannon Cancer Center
A Extension Study of GS-1101 for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116
Nashville : Sarah Cannon Cancer Center
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Nashville : Sarah Cannon Research Institute
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Nashville : Sarah Cannon Research Institute
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Nashville : SCRI
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Nashville : SCRI
Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
Nashville : Sarah Cannon Research Institute
Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Texas
Houston : MD Anderson Cancer Center
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
View More »
Abilene : US Oncology - Texas Cancer Center - Abilene (South)
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Amarillo : US Oncology - Texas Oncology, PA - Amarillo
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Amarillo : Texas Oncology
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
Arlington : US Oncology - Texas Oncology - Arlington South
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Austin : Texas Oncology
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Bedford : US Oncology - Texas Oncology, PA - Bedford
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Bryan : St. Joseph Regional Cancer Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
College Station : Scott & White Clinic
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Corpus Christi : South Texas Institute of Cancer
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Corpus Christi : Coastal Bend Cancer Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Dallas : Texas Oncology PA
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Dallas : Mary Crowley Cancer Research Centers - Medical City
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Dallas : Texas Oncology - Dallas Presbyterian
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Dallas : Texas Oncology - Medical City Dallas
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Dallas : US Oncology - Texas Oncology, PA - Dallas
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
El Paso : US Oncology - El Paso Cancer Treatment Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
El Paso : US Oncology - El Paso Cancer Treatment Center - West
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Fort Worth : Texas Oncology, P.A.
A Extension Study of GS-1101 for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116
Fort Worth : Texas Oncology, P.A.
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Fort Worth : Texas Oncology, P.A.
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Fort Worth : Texas Oncology - Fort Worth 12th Avenue
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Fort Worth : US Oncology - Southwest Fort Worth Cancer Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Fort Worth : US Oncology - Texas Oncology, PA - Fort Worth
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Fort Worth : JPS Center for Cancer Care
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Grapevine : US Oncology - Texas Oncology - Grapevine
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Houston : Site Reference ID/Investigator# 48326
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
Houston : M.D. Anderson Cancer Center
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Houston : MD Anderson Cancer Center
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Houston : MD Anderson Cancer and Research Center
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Houston : MD Anderson Cancer Center / University of Texas
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Houston : MD Anderson Cancer Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Houston : Oncology Consultants
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Houston : University of Texas MD Anderson Cancer Center
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Houston : M. D. Anderson Cancer Center at University of Texas
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
Houston : UT MD Anderson Cancer Center
Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)
Houston : Investigational Site Number 840003
Study Combining SAR245409 With Bendamustine and/or Rituximab in Subjects With Indolent Lymphoma, Mantle Cell Lymphoma & Chronic Lymphocytic Leukemia
Houston : University of Texas M.D. Anderson Cancer Center
Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias
Houston : MD Anderson Cancer
Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Houston : MD Anderson Cancer Center
TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation
Kerrville : US Oncology - San Antonio Tumor & Blood Clinic - Kerrville
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Lackland AFB : Wilford Hall Medical Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Longview : US Oncology - Longview Cancer Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Lubbock : Joe Arrington Cancer Research and Treatment Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
McAllen : US Oncology - Texas Oncology - McAllen
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Mesquite : US Oncology - Texas Oncology - Mesquite
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Midland : US Oncology - Allison Cancer Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Paris : US Oncology - Texas Oncology - Paris
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Round Rock : Texas Oncology - Central Austin Cancer Center
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
San Antonio : Cancer Care Network of South Texas
A Extension Study of GS-1101 for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116
San Antonio : Cancer Care Centers of South Texas
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
San Antonio : Cancer Care Network of South Texas
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
San Antonio : US Oncology - Cancer Care Centers of South Texas
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
San Antonio : US Oncology - San Antonio Tumor & Blood Clinic - M. Oak
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
San Antonio : University of Texas Health Science Center, San Antonio
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Sherman : US Oncology - Texas Oncology - Sherman
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Temple : Scott & White Healthcare Department of Research
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Tyler : ETMC dba Tyler Hematology Oncology
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Tyler : US Oncology - Texas Oncology - Tyler
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Tyler : ETMC dba Blood and Cancer Center - East Texas
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Waco : US Oncology - Texas Oncology Cancer Care and Research Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Weslaco : US Oncology - Texas Oncology - Weslaco
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Wichita Falls : US Oncology - Texoma Cancer Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Utah
American Fork : Central Utah Clinic
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Logan : Cache Valley Cancer Treatment & Research Clinic, Inc.
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Ogden : Northern Utah Associates
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Virginia
Charlottesville : Virginia University
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
View More »
Abingdon : Cancer Outreach Associates, PC
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Arlington : US Oncology - Arlington Fairfax Hematology Oncology
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Charlottesville : University of Virginia Health System
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Christianburg : Oncology and Hematology Assoc of SW VA DBA Blue Ridge Cancer Care
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Christiansburg : US Oncology - Onc and Hem Assoc of Southwest VA, Inc - Christiansburg
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Fairfax : Virginia Cancer Specialists, PC
A Extension Study of GS-1101 for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116
Fairfax : Virginia Cancer Specialists, PC
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Fairfax : Virginia Cancer Specialists, PC
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Fairfax : US Oncology - Fairfax Northern VA Hem-Onc PC
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Gainesville : US Oncology - Fairfax - Northern Virginia Hematology-Oncology, PC - Gainesville
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Leesburg : US Oncology - Fairfax - Northern Virginia Hem-Onc, PC - Leesburg
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Low Moor : US Oncology - Onc and Hem Assoc of Southwest VA, Inc - Low Moor
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Richlands : Virginia Oncology Care, PC
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Roanoke : Oncology and Hematology Associates of Southwest Virginia, Inc.
A Extension Study of GS-1101 for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116
Roanoke : Oncology and Hematology Associates of Southwest Virginia, Inc
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Roanoke : US Oncology - Onc and Hem Assoc of Southwest VA, Inc - Roanoke
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Salem : US Oncology - Onc and Hem Assoc of Southwest VA, Inc - Salem
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Winchester : US Oncology - Shenandoah Oncology - Winchester
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Woodbridge : US Oncology - Fairfax - Northern Virginia Hem-Onc, PC - Woodbridge
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Wytheville : US Oncology - Onc and Hem Assoc of Southwest VA, Inc - Wytheville
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Washington
Seattle : Fred Hutchinson Cancer Research Center
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
Tacoma : MultiCare Health System
A Phase I/II Study of Fludarabine, Cyclophosphamide, Rituximab, and Vorinostat Followed by Rituximab and Vorinostat Maintenance Therapy in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
View More »
Bellingham : Peace Health Medical Group
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Edmonds : Puget Sound Cancer Centers
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Edmonds : US Oncology - Puget Sound Cancer Center - Edmonds
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Everett : Providence Everett Medical Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Kennewick : Columbia Basin Hematology and Oncology
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Seattle : Site Reference ID/Investigator# 52882
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
Seattle : US Oncology - Puget Sound Cancer Center - Seattle
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Seattle : University Of Washington
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
Seattle : Seattle Cancer Care Alliance
Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies
Spokane : Cancer Care Northwest, US Oncology
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Spokane : Medical Oncology Associates PS
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Spokane : US Oncology - Cancer Care Northwest - Holland
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Spokane : US Oncology - Cancer Care Northwest - Mission
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Spokane : US Oncology - Cancer Care Northwest - Sherman
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Spokane Valley : Cancer Care Northwest
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Tacoma : Northwest Medical Specialties
A Randomized, Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia
Vancouver : US Oncology - Northwest Cancer Specialists, PC - Vancouver - 134th St
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Vancouver : US Oncology - Northwest Cancer Specialists, PC - Vancouver - 136th St.
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Walla Walla : Providence St. Mary Regional Cancer Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Yakima : Yakima Valley Memorial Hospital/North Star Lodge
A Extension Study of GS-1101 for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116
Yakima : Yakima Valley Memorial Hospital
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Yakima : Yakima Valley Memorial Hospital / North Star Lodge
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Yakima : Yakima Regional Cancer Care
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Yakima : Yakima Valley Memorial Hospital / North Star Lodge
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Yakima : US Oncology - Yakima Valley Memorial Hospital/North Star Lodge (Boyd)
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Yakima : North Star Lodge Cancer Center
Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Wisconsin
Green Bay : St. Vincent Hospital/Green Bay Oncology
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Green Bay : St Vincent Regional Cancer Center
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Green Bay : Bellin Memorial Hospital
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Janesville : Mercy Health System Heme/Onc
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
LaCrosse : Gundersen Clinic
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
View More »
Madison : Site Reference ID/Investigator# 56811
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
Madison : University of Wisconsin
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Madison : University of Wisconsin Carbone Cancer Center
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Madison : University of Wisconsin
Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies
Marshfield : Marshfield Clinic
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Milwaukee : Medical College of Wisconsin
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Oconomowoc : Oconomowoc Memorial Hospital
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Waukesha : Waukesha Memorial Hospital
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Waukesha : Waukesha Memorial Hospital
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Wisconsin Rapids : Riverview Hospital
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Australia
Nedlands : Sir Charles Gairdner Hospital
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
View More »
East Melbourne : Site Reference ID/Investigator# 48323
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
East Melbourne : Site Reference ID/Investigator# 70394
A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed or Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Parkville : Site Reference ID/Investigator# 48322
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
Parkville : Site Reference ID/Investigator# 70393
A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed or Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Austria
Feldkirch : LKH Feldkirch, Interne E
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
Hall : A.ö. Bezirkskrankenhaus Hall in Tirol, Innere Medizin / Hämato - Onkologie
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
Innsbruck : Universitätsklinik für Innere Medizin Innsbruck, Klinische Abteilung für Hämatologie und Onkologie
Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL
Innsbruck : GSK Investigational Site
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Innsbruck : Universitätsklinik Innsbruck, Innere MEdizin IV / Hämato-Onkologie
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
View More »
Krems : Landesklinikum Krems, Hämato-onkologisches Service
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
Kufstein : A.ö. Bezirkskrankenhaus Kufstein, Innere Medizin / Hämatologie / Onkologie
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
Linz : GSK Investigational Site
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Linz : AKH Linz, Department für Innere Medizin 3
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
Salzburg : Universitätsklinik der PMU Salzburg, Univ-Klinik für Innere Medizin III
Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL
Salzburg : GSK Investigational Site
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Salzburg : Universitätsklinik der PMU Salzburg, Univ-Klinik für Innere Medizin
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
Steyr : Landeskrankenhaus Steyr, Innere Medizin, Hämatologie, Onkologie
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
Wels : Klinikum Wels-Grieskirchen GmbH, Abteilung für Innere Medizin IV
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
Wien : AKH Wien, Klinische Abteilung für Hämatologie und Hämostaseologie
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
Wien : Hanusch Krankenhaus, 3. Med. Abtlg.
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
Belgium
Antwerpen : Ziekenhuisnetwerk Antwerpen - AZ Stuivenberg
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Brussels : Institute Jules Bordet, Department of Hematology
NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)
Brussels : Cliniques universitaires Saint-Luc
NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)
Leuven : University Hospital Gasthuisberg, Department of Hematology
NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)
Bulgaria
Sofia : GSK Investigational Site
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Canada
Toronto : Univ. Health Network-Princess Margaret Hospital
A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia
Toronto : University Health Network - Princess Margaret Hospital
Open-Label Study of Lenalidomide in Combination With Oral Dexamethasone in the Treatment of Previously Untreated, Symptomatic Patients With Chronic Lymphocytic Leukemia
Winnipeg : CancerCare Manitoba
A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia
China
Tianjin : Hematologic hospital of Chinese academy of medical sciences
Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia
Czech Republic
Brno : FN Brno
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
Hradec Kralove : FN Hradec Kralove
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
Olomouc : FN Olomouc
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
Praha : VFN Praha 2
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
Praha : FN Kralovske Vinohrady
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
France
Clermont-Ferrand Cedex 1 : GSK Investigational Site
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Courbevoie : Laboratoires Merck Sharp & Dohme - Chibret
A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974 AM1)
Creteil :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Lille cedex : GSK Investigational Site
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Montpellier :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
View More »
Tours :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Germany
Cologne : German CLL Study Group
A Phase 3 Study of the Efficacy and Safety of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy
Cologne : University Hospital Cologne
A Phase 3 Study of the Efficacy and Safety of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy
Dresden : GSK Investigational Site
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Essen : GSK Investigational Site
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Koblenz : GSK Investigational Site
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
View More »
Regensburg : GSK Investigational Site
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Hungary
Budapest : GSK Investigational Site
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Debrecen : GSK Investigational Site
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Szombathely : GSK Investigational Site
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Ireland
Dublin : Hermitage Medical Clinic
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
Israel
Jerusalem : GSK Investigational Site
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Naharia :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Rehovot : Kaplan Medical Center
The Humanized Monoclonal Antibody Milatuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)
Italy
Milano : Universita Vita-Salute San Raffaele
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
View More »
Bergamo : A.O. Ospedali Riuniti di Bergamo U.S.C. Ematologia
Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia
Bologna : University Hospital, Institute of Hematology and Oncology
NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)
Brescia : GSK Investigational Site
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Brescia : Presidi Ospedalieri Spedali Civili di Brescia Divisione di Ematologia
Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia
Como : Ospedale Valduce S.C. Medicina Interna Sez. Ematologia
Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia
Cremona : Istituti Ospitalieri di Cremona U.O.C. Ematologia e Centro Trapianti Midollo Osseo
Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia
Genova : University Hospital San Martino, Department of Hematology and Oncology
NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)
Legnano : Azienda Ospedaliera Ospedale Civile di Legnano U.O. Medicina Interna
Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia
Lodi : ASL della Provincia di Lodi Presidio Ospedaliero di Lodi Dipartimento di Medicina Interna
Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia
Milano : Ospedale San Raffaele S.r.l.
A Extension Study of GS-1101 for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116
Milano : Ospedale San Raffaele S.r.l.
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Milano : Ospedale San Raffaele S.r.l.
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Milano : Niguarda Ca'Granda Hospital
NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)
Milano : University Scientific Research Institute San Raffaele
NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)
Milano : GSK Investigational Site
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Milano : Ospedale Cà Granda - Niguarda S.C: Ematologia
Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia
Milano : IRCCS Fondazione Centro S. Raffaele del Monte Tabor Università Vita-Salute Dipartimento di Medicina Interna
Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia
Milano : Ospedale Maggiore Policlinico Università di Milano Istituto di Ematologia
Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia
Monza : Azienda Ospedaliera San Gerardo di Monza U.O. Ematologia
Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia
Novara : Azienda ospedaliera-universitaria Maggiore della Carità SCDU Ematologia
Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia
Padova : University School of Medicine, Department of Hematology
NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)
Pavia : IRCCS Policlinico San Matteo Pavia Istituto di Ematologia
Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia
Rozzano : IRCCS Istituto clinico Humanitas di Rozzano Dipartimento di Ematologia
Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia
Torino : A.O.U. Le Molinette San Giovanni Battista Divisione di Ematologia
Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia
Venezia Mestre : Ospedale dell' Angelo
Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia
Poland
Brzozow :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Chorzow :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Chorzow : GSK Investigational Site
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Opole :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Wroclaw : GSK Investigational Site
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Russian Federation
Arkhangelsk :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Chelyabinsk : GSK Investigational Site
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Ekaterinburg :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Moscow : GSK Investigational Site
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Nizhniy Novgorod :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
View More »
St. Petersburg : GSK Investigational Site
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
St.-Petersburg :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
St'Petersburg : GSK Investigational Site
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Singapore
Singapore : GSK Investigational Site
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Slovakia
Bansky Bystrica : F.D. Rossevelt hospital
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
Bratislava : GSK Investigational Site
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Bratislava : Narodny onkologicky ustav
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
Bratislava : FNsP sv. Cyrila a Metoda
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
Kosice : FNsP L.Pasteura
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
View More »
Martin : Martinska fakultna nemocnica
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
Presov : FNsP J.A. Reimana
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
Spain
Barcelona : Hospital de Ia Santa Creu i Sant Pau
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
Barcelona : Hospital Clinic de Barcelona
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
Coruna : Hospital Universitario A Coruna
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
Madrid : Hospital de Madrid Norte-San Chinarro
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
Madrid : Hospital Puerta de Hierro
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
Pamplona : Clinica Universitaria de Navarra
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
View More »
Badalona : Hospital Germans Trias i Pujol
Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation
Barcelona : Hospital de la Santa Creu i Sant Pau
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Barcelona : Hospital de la Santa Creu Sant Pau
Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation
Barcelona : Hospital Vall d'Hebron
Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation
Córdoba : Hospital Universitario Reina Sofía
Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia
Córdoba : Hospital Universitario Reina Sofía
Activity and Safety of Lenalidomide and Rituximab (LenRtx) as Non-chemotherapy Based Therapy for Patients With Chronic Lymphocytic Leukemia
Hospitalet de Llobregat : Institut Catala d'Oncologia
Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation
Madrid : Fundación MD Anderson Internacional
Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia
Madrid : Hospital Universitario La Paz
Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia
Madrid : Fundación MD Anderson Internacional
Activity and Safety of Lenalidomide and Rituximab (LenRtx) as Non-chemotherapy Based Therapy for Patients With Chronic Lymphocytic Leukemia
Madrid : Hospital Universitario La Paz
Activity and Safety of Lenalidomide and Rituximab (LenRtx) as Non-chemotherapy Based Therapy for Patients With Chronic Lymphocytic Leukemia
Madrid : Hospital La Princesa
Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation
Madrid : Hospital Puerta de Hierro
Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation
Oviedo : Hospital Central de Asturias
Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation
Salamanca : Hospital Clínico de Salamanca
Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia
Salamanca : Hospital Clínico de Salamanca
Activity and Safety of Lenalidomide and Rituximab (LenRtx) as Non-chemotherapy Based Therapy for Patients With Chronic Lymphocytic Leukemia
Sevilla : Hospital Virgen del Rocío
Activity and Safety of Lenalidomide and Rituximab (LenRtx) as Non-chemotherapy Based Therapy for Patients With Chronic Lymphocytic Leukemia
Valencia : Hospital Clínico Universitario de Valencia
Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia
Valencia : Hospital Clínico Universitario de Valencia
Activity and Safety of Lenalidomide and Rituximab (LenRtx) as Non-chemotherapy Based Therapy for Patients With Chronic Lymphocytic Leukemia
Valencia : Hospital Clinico
Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation
Valencia : Hospital La Fe
Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation
Zaragoza : Hospital Universitario Miguel Servet
Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia
Zaragoza : Hospital Universitario Miguel Servet
Activity and Safety of Lenalidomide and Rituximab (LenRtx) as Non-chemotherapy Based Therapy for Patients With Chronic Lymphocytic Leukemia
Sweden
Göteborg :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Göteborg : GSK Investigational Site
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Stockholm : GSK Investigational Site
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Uppsala : GSK Investigational Site
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Turkey
Ankara :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Istanbul :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Izmir :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Kayseri :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Ukraine
Cherkasy : GSK Investigational Site
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Dnipropetrovsk : GSK Investigational Site
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Donetsk : GSK Investigational Site
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Kharkiv : GSK Investigational Site
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Khmelnytskyi : GSK Investigational Site
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
View More »
Kyiv : GSK Investigational Site
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Lviv : GSK Investigational Site
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Makiivka : GSK Investigational Site
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Vinnitsa : GSK Investigational Site
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
United Kingdom
Bournemouth : The Royal Marsden Hospital and The Institute of Cancer Research
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
Canterbury : Kent & Canterbury Hospital
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
Colchester : Colchester Hospital University
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
Leeds : Kent & Canterbury Hospital
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
Liverpool : Royal Liverpool University Hospital
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
London : Kings College Hospital. NHS Foundation Trust
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
Nottingham : Nottingham City Hospital
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
Southampton : Southampton General Hospital
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
Sutton : The Royal Marsden Hospital and The Institute of Cancer Research
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
View More »
Birmingham :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Bournemouth : Royal Bournemouth Hospital
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Harrow :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Leeds : St James's University Hospital
A Extension Study of GS-1101 for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116
Leeds : St James's University Hospital
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
London : King's College Hospital
Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies
London : University College London
Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies
Manchester : The Christie NHS Foundation
Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies
Newcastle upon Tyne : University of Newcastle Upon Tyne, NHS Foundation Trust
Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies
Orpington : Princess Royal University Hospital
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Oxford : GSK Investigational Site
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Plymouth :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Southampton : Southampton General Hospital
A Extension Study of GS-1101 for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116
Southampton : Southampton General Hospital
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Torquay : Torbay District General Hospital
A Extension Study of GS-1101 for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116
Torquay : Torbay District General Hospital
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Truro : Royal Cornwall Hospital
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Yeovil : Yeovil District Hospital
A Extension Study of GS-1101 for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116
Yeovil : Yeovil District Hospital
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
